BIO-key Q2 Loss Narrows, But $2.5M Warrant Exercise and Debt Exchanges Add Dilution
BKYI sits 26% above its 52-week low of $3.1.
Summary
BIO-key's Q2 loss narrowed, but subsequent warrant exercises and debt-for-equity exchanges raised $2.5M while adding substantial dilution.
Key Events · Earnings and Guidance · BKYI
-
Q2 Revenue Up, Loss Narrows
Revenue rose 13% to $1.92M; net loss improved to $576,852 from $1.17M in Q2 2025.
-
Going Concern Warning Persists
Company states it does not have enough cash for 12 months of operations and requires about $750,000 per month.
-
$2.5M Warrant Exercise
On August 11, 2026, existing investor exercised 618,334 warrants at $4.06 per share, generating $2.5M gross proceeds and issuing additional warrants for 1,236,668 shares.
-
Debt Exchanged for Equity
In July and August 2026, $350,000 of the 2025 Note was exchanged for 81,100 shares, reducing debt to about $325,000.
Analysis · BKYI · Technology
BIO-key's Q2 2026 revenue rose 13% to $1.92M and net loss narrowed to $576,852 from $1.17M a year ago, but the company still burns cash and has a going concern warning. The real story is the subsequent events: on August 11, the company raised $2.5M by exercising warrants at $4.06 per share, issuing 618,334 shares and additional warrants for 1,236,668 shares. That's highly dilutive for a company with only 1.44M shares outstanding. The company also exchanged $350,000 of debt for 81,100 shares, further diluting holders. These moves provide short-term cash but significantly increase the share count and potential future dilution.
At the time of this filing, BKYI was trading at $3.90 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $3.10 to $19.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.